Main Menu

The Centers for Disease Control and Prevention (CDC) and the National Institute for Allergy and Infectious Diseases (NIAID) have been rewarded for their partnership from the 2021 Federal Laboratory Consortium (FLC) awards. The CDC and NIAID had already developed a new approach to sharing samples during a Public Health Emergency of International Concern (PHEIC) during the Zika pandemic, which enabled them to respond quickly and efficiently to access and share samples of SARS-CoV-2 early in the outbreak.

Within hours of the public release of the viral genome sequence, scientists at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) and their collaborators engineered a key protein from SARS-CoV-2, the virus that causes COVID-19, to enable its study as a vaccine candidate and for research applications.

The Technology Transfer and Intellectual Property Office (TTIPO)

Originally established to study influenza, a partnership between NIAID and biotechnology company AbCellera quickly pivoted to become a major player in the development of antibodybased COVID-19 therapies. One of those therapies, bamlanivimab, has been authorized to treat mild to moderate COVID-19 symptoms in patients who are at risk for more severe disease, when combined with another antibody.